Expression and Immunotherapeutic Targeting of the SSX Family of Cancer–Testis Antigens in Prostate Cancer
- 30 October 2011
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 71 (21), 6785-6795
- https://doi.org/10.1158/0008-5472.can-11-2127
Abstract
Recent U.S. Food and Drug Administration approval of the first immunotherapy for prostate cancer encourages efforts to improve immune targeting of this disease. The synovial sarcoma X chromosome breakpoint (SSX) proteins comprise a set of cancer–testis antigens that are upregulated in MHC class I–deficient germline cells and in various types of advanced cancers with a poor prognosis. Humoral and cell-mediated immune responses to the SSX family member SSX2 can arise spontaneously in prostate cancer patients. Thus, SSX2 and other proteins of the SSX family may offer useful targets for tumor immunotherapy. In this study, we evaluated the expression of SSX family members in prostate cancer cell lines and tumor biopsies to identify which members might be most appropriate for immune targeting. We found that SSX2 was expressed most frequently in prostate cell lines, but that SSX1 and SSX5 were also expressed after treatment with the DNA demethylating agent 5-aza-2′-deoxycytidine. Immunohistochemical analysis of microarrayed tissue biopsies confirmed a differential level of SSX protein expression in human prostate cancers. Notably, SSX expression in patient tumor samples was restricted to metastatic lesions (5/22; 23%) and no expression was detected in primary prostate tumors examined (0/73; P < 0.001). We determined that cross-reactive immune responses to a dominant HLA-A2–specific SSX epitope (p103-111) could be elicited by immunization of A2/DR1 transgenic mice with SSX vaccines. Our findings suggest that multiple SSX family members are expressed in metastatic prostate cancers which are amenable to simultaneous targeting. Cancer Res; 71(21); 6785–95. ©2011 AACR.Other Versions
This publication has 44 references indexed in Scilit:
- Vaccines Targeting the Cancer-testis Antigen SSX-2 Elicit HLA-A2 Epitope-specific Cytolytic T CellsJournal of Immunotherapy, 2011
- CD8+ T cells specific for the androgen receptor are common in patients with prostate cancer and are able to lyse prostate tumor cellsCancer Immunology, Immunotherapy, 2011
- Sipuleucel-T Immunotherapy for Castration-Resistant Prostate CancerThe New England Journal of Medicine, 2010
- HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphataseCancer Immunology, Immunotherapy, 2010
- The SSX Family of Cancer-Testis Antigens as Target Proteins for Tumor TherapyJournal of Immunology Research, 2010
- Safety and Immunological Efficacy of a DNA Vaccine Encoding Prostatic Acid Phosphatase in Patients With Stage D0 Prostate CancerJournal of Clinical Oncology, 2009
- Validation of Reference Genes in Cervical Cell Samples from Human Papillomavirus-Infected and -Uninfected Women for Quantitative Reverse Transcription-PCR AssaysClinical and Vaccine Immunology, 2008
- Tumor immunoediting and immunosculpting pathways to cancer progressionSeminars in Cancer Biology, 2007
- The Human Genome Browser at UCSCGenome Research, 2002
- A new mathematical model for relative quantification in real-time RT-PCRNucleic Acids Research, 2001